



WEDNESDAY 15th March 2017 COMMENCING 9.30 AM

AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting**

1/AWMSG/0317

To protect commercial confidentiality the following appraisals will be held in private

5. **Appraisal 1: Full Submission (WPAS)**
Ivacaftor (Kalydeco[®]) for the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CFTR gene
2/AWMSG/0317
Appendices
6. **Appraisal 2: Full Submission (WPAS)**
Bevacizumab (Avastin[®]) in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix
3/AWMSG/0317
Appendices
7. **Appraisal 3: Full Submission (WPAS)**
Idelalisib (Zydelig[®]) as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment
4/AWMSG/0317
Appendices

The meeting will now open to the public (approximately 12.00pm)

8. **Chairman's report (verbal update)**

Date of next meeting: 26th April 2017 in Cardiff